Karyopharm announced that four posters will be presented at the upcoming American Society of Clinical Oncology, or ASCO, 2018 annual meeting. Among the poster presentations will be results from the company’s Phase 2 SEAL study evaluating selinexor, its lead, oral Sine compound, in patients with advanced de-differentiated liposarcoma. The remaining posters will highlight clinical and preclinical data from ongoing investigator-sponsored trials evaluating selinexor in combination with other anti-cancer agents.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.